Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Renin inhibition.

Michel Azizi1

  • 1Université Paris Descartes, Faculté de Médecine, and Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France. michel.azizi@egp.aphp.fr

Current Opinion in Nephrology and Hypertension
|August 18, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient perspective on the management of hypertension in 7 European countries: insights from a survey of 4001 patients.

Polish archives of internal medicine·2026
Same author

Pregnancy-Related Complications in Primary Aldosteronism: A European Survey.

Hypertension (Dallas, Tex. : 1979)·2026
Same author

CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum.

Cardiovascular diabetology·2026
Same author

Predicting primary aldosteronism: risk stratification-based and machine learning-based models.

European journal of preventive cardiology·2026
Same author

Empowering Patients and Clinicians: LLMs in Hypertension Care, A Scoping Review.

Hypertension (Dallas, Tex. : 1979)·2026
Same author

Diagnosis and Management of Resistant Hypertension: A Review.

JAMA·2026

Aliskiren, a new oral renin inhibitor, effectively lowers blood pressure in hypertensive patients. Renin inhibition offers a novel strategy for optimizing renin-angiotensin system blockade in cardiovascular and renal disorders.

Area of Science:

  • Cardiovascular Medicine
  • Nephrology
  • Pharmacology

Background:

  • The renin-angiotensin system (RAS) is a key regulator of blood pressure and fluid balance.
  • Previous attempts to inhibit renin faced challenges, but advancements in molecular modeling and X-ray crystallography enabled the development of new inhibitors.
  • Aliskiren represents a novel, orally active renin inhibitor.

Purpose of the Study:

  • To review the current understanding and clinical data on aliskiren, a direct renin inhibitor.
  • To evaluate the potential of aliskiren in managing cardiovascular and renal disorders.
  • To compare renin inhibition with other RAS blockade strategies.

Main Methods:

  • Review of preclinical and clinical data on aliskiren.
  • Analysis of blood pressure response to aliskiren in hypertensive patients.

Related Experiment Videos

  • Comparison of biochemical consequences of renin inhibition versus other RAS blockade methods.

    • Main Results:

    • Once-daily aliskiren administration effectively lowers blood pressure in hypertensive patients, comparable to or exceeding established angiotensin II type 1 receptor blockers.
    • Aliskiren further reduces blood pressure when combined with hydrochlorothiazide.
    • Renin inhibition exhibits distinct biochemical effects compared to angiotensin I-converting enzyme inhibition and angiotensin II antagonism, particularly concerning angiotensin profiles and interactions with other pathways.

    Conclusions:

    • Direct renin inhibition with aliskiren is a promising therapeutic option for hypertension.
    • Optimizing RAS blockade for maximal cardiovascular and renal benefits requires further investigation.
    • Renin inhibition offers a new approach to achieve complete RAS quiescence, warranting further study.